title: Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis.
abstract: Results of recent animal studies have lent support to the hypothesis that hyperlipidaemia may contribute to renal injury. This report documents the case of a 15-year-old boy with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis (FGS) who showed an improvement in renal function and proteinuria as a result of treatment with low-density lipoprotein aphaeresis (LDL-A) combined with pravastatin. Although further work is required to determine the efficacy of lipid-lowering therapy in progressive glomerular disease in humans, the combination of LDL-A and pravastatin is likely be included in the choice of treatment modalities available for patients with drug-resistant nephrotic syndrome due to FGS.
authors: Department of Paediatric Nephrology, Tokyo Women's Medical College, Japan.
authors: M
authors: M
authors: Hattori
authors: K
authors: K
authors: Ito
authors: H
authors: H
authors: Kawaguchi
authors: T
authors: T
authors: Tanaka
authors: R
authors: R
authors: Kubota
authors: M
authors: M
authors: Khono
mesh_terms: D000293:Adolescent; D001781:Blood Component Removal; D003131:Combined Modality Therapy; D004351:Drug Resistance; D005923:Glomerulosclerosis, Focal Segmental / Q000150:complications*; D006801:Humans; D006949:Hyperlipidemias / Q000628:therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007677:Kidney Function Tests; D008077:Lipoproteins, LDL / Q000627:therapeutic use*; D008297:Male; D009404:Nephrotic Syndrome / Q000209:etiology / Q000628:therapy*; D017035:Pravastatin / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D008077:Lipoproteins, LDL; D017035:Pravastatin